Developer docs
API playgroundTry for free, no card

Search company profiles

Human Metabolome Technologies

Full company profile

uuid0035cqd

Namestring
Human Metabolome Technologies
Legal namestring
Human Metabolome Technologies, Inc.
Company typeenum
Private
Founded yearint
2003
Descriptiontext

Human Metabolome Technologies, Inc. (HMT) is a Japan-based biotechnology and metabolomics contract research company founded on July 1, 2003, by Professor Tomoyoshi Soga (developer of the CE-MS method at Keio University in 2002) and Professor Masaru Tomita, Director of Keio's Institute for Advanced Biosciences. The company is headquartered at 246-2 Mizukami Kakuganji, Tsuruoka, Yamagata, Japan, with sales operations in Tokyo (Chuo-ku) and a US subsidiary (Human Metabolome Technologies America, Inc.) in Boston, MA. HMT is listed on the Tokyo Stock Exchange (ticker: 6090) with 51–100 employees.

HMT's core technology platform is Capillary Electrophoresis Mass Spectrometry (CE-MS), developed jointly with Keio University and Agilent Technologies, with LC-MS and MS/MS platforms supplementing for lipophilic and broader-coverage metabolite analysis. The service catalog spans OMEGA Scan (untargeted polar metabolomics, 1.5–2x more metabolites vs. basic scan), LC-OMEGA Scan (untargeted lipidomics), Mediator Scan (400 lipid mediators), C-SCOPE (targeted quantitative glycolytic panel of 116 metabolites with three-point calibration), F-SCOPE (isotope flux analysis for C13/N15 tracing), D/L amino acid isomer analysis, and a patented peptidomics approach covering 1,000–10,000 mass range. The full platform measures more than 1,700 metabolites as of November 2025. Reports include PCA, HCA heat maps, pathway mapping, and expert biochemist interpretation, with standard turnaround of 4–8 weeks.

HMT operates a professional-services / CRO business model with quote-based, pay-as-you-go pricing that varies by analysis plan, sample count, and optional add-ons. The company serves pharmaceutical and biotechnology companies (drug discovery, biomarker, preclinical/clinical research), academic and medical research institutions (infectious disease, oncology, neuroscience, regenerative medicine), food and functional ingredient manufacturers (health-claim support, fermentation optimization), chemical/industrial biotech companies (metabolic flux analysis), and government/public-health research organizations. Distribution is hybrid: direct sales in Japan and North America, plus authorized distributors LKLS Co., Ltd. in Korea and GenDiscovery Biotechnology in Taiwan. Marketing is centered on recurring webinars, the Metabolite of the Week educational series, active participation in Japanese scientific conferences (BioJapan, Japanese Society for Bioscience/Biotechnology/Agricultural Chemistry, etc.), and direct inquiry handling through the website and account managers. Complementary revenue streams include biomarker discovery, healthcare solution packages (functional ingredient development, health claim prediction), analysis kits and consumables (centrifugal filters, miRNA panels), and strategic partnerships with MiRXES (miRNA), AutoPhagyGO (autophagy), and AIREX.

Short descriptiontext

Human Metabolome Technologies is a Japan-based contract research organization that provides CE-MS and LC-MS-based metabolomics profiling and biomarker discovery services to pharmaceutical, academic, food/functional-ingredient, and government research customers across Asia-Pacific, North America, and Europe.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
metabolomics services, mass spectrometry analysis, biomarker discovery, CE-MS platforms, metabolome profiling
Industry5 codes
PRIMARYHLAGANAG
Metabolomics & Lipidomics Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
SIC code3 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
  • Services-Testing Laboratories8734
Product category
Metabolomics Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Metabolome Analysis Services
TypeProfessional Services
Description

HMT's primary revenue stream, offering commissioned metabolomics analysis services across multiple platforms (CE-MS, LC-MS, MS/MS). Services include various analysis plans such as Basic Scan, Advanced Scan, ω Scan, C-SCOPE, F-SCOPE, Dual Scan, Mediator Scan, and optional add-ons. Pricing is quote-based and varies by plan, sample count, and optional analyses. Reports are delivered in PDF with Excel numerical data within 4–8 weeks typically.

humanmetabolome.com
2Biomarker Discovery
TypeSubscription Recurring
Description

HMT conducts research and development of biomarkers related to mental illness and lifestyle diseases, contributing to preventive and personalized medicine. This includes support for cohort study-based biomarker searches, collaborating with academic and clinical partners.

humanmetabolome.com
3Healthcare Solution Services
TypeProfessional Services
Description

HMT provides comprehensive support services for functional ingredient development, including biomarker exploration packages, promotion data packages, health claim prediction packages, and fermentation upcycling material development support. Also includes proteome analysis, human skin gas measurement, autophagy activity evaluation, miRNA analysis, and exosome-related analysis services.

humanmetabolome.com
4Analysis Kit and Consumables Sales
TypeHardware Sales
Description

HMT sells centrifugal filtration filters and miRNA analysis panels/primers as consumable products alongside its service offerings.

humanmetabolome.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details2 tiers
1C-SCOPE and quantitative panels — absolute concentration reporting
ModelUnit PricingBilling cadencePay-as-you-go
Notes

C-SCOPE and Q-OPTION 110 provide quantitative concentration values using multi-point calibration. Price varies by sample count and number of metabolites quantified.

humanmetabolome.com
2Non-quantitative panels (Basic Scan, Advanced Scan, ω Scan, Dual Scan, Mediator Scan, F-SCOPE) — relative area value reporting
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Most analysis plans report relative area values. Price varies by plan, sample count, and optional add-ons. Minimum sample requirements vary by plan: Mediator Scan minimum 10 samples, C-SCOPE minimum 6 samples.

humanmetabolome.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Human Metabolome Technologies (HMT) provides commissioned metabolome analysis services using proprietary Capillary Electrophoresis Mass Spectrometry (CE-MS) and Liquid Chromatography Mass Spectrometry (LC-MS) platforms. The company offers targeted and untargeted metabolomics profiling across more than 1,700 metabolites from biological samples including biofluids, tissues, cells, food, and microbial samples, serving pharmaceutical, academic, food science, and clinical research customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over 1,700 metabolites measurable in metabolome analysis service as of November 2025
+3 more records
Product overview1 text field

Human Metabolome Technologies (HMT) offers a comprehensive metabolomics service platform based on capillary electrophoresis mass spectrometry (CE-MS) and liquid chromatography mass spectrometry (LC-MS) technologies. The core offerings include OMEGA Scan for untargeted polar metabolite analysis, Basic/Advanced Scan for hydrophilic profiling, C-SCOPE for quantitative glycolytic panel analysis, Mediator Scan for 400 lipid mediator targets, Dual Scan for combined polar/lipophilic analysis, F-SCOPE for isotope flux analysis, and LC-OMEGA for lipid analysis. Supporting services include biomarker discovery, peptidomics, amino acid analysis, D/L amino acid isomers, tryptophan metabolism panels, sample quality analysis, and flux analysis. HMT also provides specialized services including cohort study packs, proteome analysis, skin gas measurement, autophagy assessment, miRNA analysis (via MiRXES partnership), exosome analysis, and functional ingredient development support with health claim prediction. The platform covers applications in infectious disease, cancer metabolism, microbiome, metabolic diseases, neuroscience, regenerative medicine, and food metabolomics.

Product and service30 records
1OMEGA Scan
CategoryUntargeted Metabolomics Service
Description

HMT's signature untargeted metabolomics platform based on CE-MS, optimized for high-sensitivity analysis of polar, semi-volatile, hydrophilic, and charged metabolites from any biological source. Detects 1.5 to 2 times more metabolites than standard Basic Scan.

2Basic Scan
CategoryUntargeted Metabolomics Service
Description

Multi-purpose CE-MS profiling service for a wide range of hydrophilic metabolites, including energy metabolism intermediates, for general screening applications.

3Advanced Scan
CategoryUntargeted Metabolomics Service
Description

Comprehensive CE-MS analysis including unknown metabolites for extended-range hydrophilic metabolite profiling with identification capabilities.

4C-SCOPE Targeted Glycolytic Panel
CategoryTargeted Metabolomics Service
Description

Targeted quantitative panel of 116 metabolites in the glycolytic pathway, pentose phosphate pathway, TCA cycle, amino acids, and urea cycle using three-point calibration for absolute quantification. Used for cancer, Warburg effect, and mitochondrial metabolism research.

5Q110 and Q353 Quantitative Polar Panels
CategoryTargeted Metabolomics Service
Description

Targeted panels of 110 or 353 polar metabolites respectively, representing a wide range of metabolite classes. Used with untargeted metabolomics such as OMEGA Scan for comprehensive profiling.

6Mediator Scan (MSCAN)
CategoryTargeted Lipidomics Service
Description

Targeted panel covering 400 bioactive lipids including oxylipins, omega fatty acids, inflammatory lipids (HETEs), EPA, DHA, corticosteroids, lysophospholipids, and middle to very long chain acyl carnitines. Used for inflammation and immune response studies.

7Dual Scan
CategoryCombined Metabolomics Service
Description

Low-cost option profiling both polar and lipophilic metabolites using Agilent CE-TOFMS system. Identifies more than 1,300 metabolites covering over 1,000 hydrophilic/ionic and 300 lipophilic metabolites. Ideal for plant extracts, agricultural products, and fermentation broths.

8LC-OMEGA Scan
CategoryUntargeted Lipidomics Service
Description

Untargeted lipid metabolite analysis using HPLC-MS methods focusing on lipophilic metabolites with high-resolution chromatography and high-resolution high-sensitivity FTMS.

9F-SCOPE Targeted Flux Panel
CategoryMetabolic Flux Analysis Service
Description

Targets 54 polar metabolites in the glycolytic pathway, TCA cycle, purines and pyrimidines, urea cycle and amino acids to measure C13 and N15 heavy atom labeled metabolite transformations for metabolic flux analysis. Used for in-vivo measurements of glucose oxidation and glutamine metabolism.

10Peptidomics
CategoryPeptidomics Service
Description

Patented peptidomics approach offering a small peptide library (100 to 1,000 mass) with OMEGA Scan advanced option for bioactive 2-mers to 5-mers, and a patented approach covering 1,000 to 10,000 mass mid-molecular weight range not accessible by standard metabolomics.

11D/L Amino Acids Panel
CategoryTargeted Amino Acid Analysis Service
Description

Unique targeted panel of 25 D and L amino acids using derivatization with an optical-center ligand that separates and identifies D and L isomers not resolvable in typical metabolomic chromatography.

12Tryptophan Metabolism Pathway Panel
CategoryTargeted Pathway Analysis Service
Description

Targeted platform of the tryptophan pathway for inflammation, immune system and neurological condition research.

13Amino Acid Analysis
CategoryTargeted Amino Acid Analysis Service
Description

Measures all 20 common amino acids including citrulline and ornithine for biological function analysis including antioxidant activity and ATP synthesis.

14Sample Quality Analysis
CategoryQuality Control Service
Description

Data assessment evaluating sample stability using known markers for thermal degradation, hemolysis, platelet contamination and long-term storage to survey biofluids and tissues prior to statistical analysis.

15Fit-4 Purpose Assays
CategoryCustom Assay Service
Description

Full-service quantitative assays using various forms of capillary electrophoresis and liquid chromatography mass spectrometry, with options validated for research or clinical use.

16Flux Analysis
CategoryMetabolic Flux Analysis Service
Description

Metabolic flux determination using isotopically labeled substrates to trace metabolites and elucidate active metabolic pathways.

17Biomarker Discovery
CategoryBiomarker Discovery Service
Description

Metabolomic profiling service supporting biomarker discovery for disease detection, diagnostic markers, and predictive markers in clinical studies.

18Cohort Study Pack
CategoryCohort Study Service
Description

Comprehensive support service for cohort studies including metabolomics analysis and biomarker discovery for population health research, incorporating large-scale data correction methodology.

19Metabololo-Index (メタボロインデックス)
CategoryBiomarker Index Service
Description

Biomarker index service using metabolomic data and machine learning algorithms for health assessment and disease prediction.

20Proteome Analysis
CategoryProteomics Service
Description

Proteomics analysis service complementing metabolome analysis for comprehensive molecular profiling.

21Human Skin Gas Measurement
CategorySpecialty Metabolomics Service
Description

Specialized analysis service for measuring volatile metabolites from human skin for non-invasive metabolic profiling.

22Autophagy Activity Assessment
CategorySpecialty Metabolomics Service
Description

Service for evaluating autophagy activity through metabolomic analysis, supporting research in cellular degradation and renewal processes.

23miRNA Analysis (MiRXES ID3EAL)
CategoryRNA Analysis Service
Description

miRNA analysis service using ID3EAL technology through partnership with MiRXES for gene expression analysis.

24Exosome-Related Analysis
CategoryExosome Analysis Service
Description

Analysis service for exosome samples supporting extracellular vesicle research and biomarker discovery.

25Functional Ingredient Development Support Service
CategoryFunctional Food Support Service
Description

Comprehensive support package including functional ingredient exploration, promotion data, and health claim prediction packages for functional food development.

26Health Claim Prediction Package
CategoryFunctional Food Support Service
Description

Predictive service using proprietary algorithms to predict health claims for functional foods based on metabolomic analysis.

27Bio-manufacturing Production Enhancement Support Service
CategoryIndustrial Bioprocessing Service
Description

Support service for bio-manufacturing productivity enhancement using metabolomics for process optimization, including fermentation upcycling material development support.

28Analysis Kits and Consumables
CategoryConsumables and Kits
Description

Sale of centrifugal filter units and miRNA analysis panels and primers for customer self-directed analysis, sold alongside service offerings.

29Food Metabolomics Application
CategoryApplication Area
Description

Application offering covering analysis of food components, metabolic changes during manufacturing, preparation and storage, functional component exploration, and dietary effect assessment for food science researchers and manufacturers.

30Regenerative Medicine Application
CategoryApplication Area
Description

Application offering supporting stem cell research, cell differentiation studies, and regenerative medicine applications for researchers in regenerative medicine and cell biology.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-08-01
Description

AutoPhagyGO Inc. and HMT entered a business partnership to advance autophagy research and social implementation. The partnership involves joint webinars and collaboration on autophagy activity evaluation services. In 2025, the collaboration achieved the world's first 'autophagy certification' for NMN using metabolomics evidence, demonstrating the application of HMT's metabolomics in substantiating health claims.

2AIREX Co., Ltd.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-05-01
Description

AIREX and HMT entered a business partnership. Details of the collaboration are not fully specified in available sources but the partnership is listed as a formal business alliance alongside other strategic partnerships.

humanmetabolome.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-09-01
Description

MiRXES and HMT entered a business partnership for miRNA analysis services. HMT provides commissioned miRNA analysis services using MiRXES's ID3EAL technology, and offers MiRXES miRNA analysis panels and primers for sale. The partnership expands HMT's service offerings beyond metabolomics into RNA analysis.

4Hirosaki University COI
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-05-01
Description

HMT established a joint course 'Department of Metabolomics Innovation' at Hirosaki University Graduate School of Medicine in May 2019. The collaboration involves metabolome analysis of plasma and urine samples from participants in the Iwaki Health Promotion Project (cohort of over 2,000 participants with 10+ years of health data). Joint research has produced published methods for large-scale metabolome data correction, enabling reliable biomarker discovery in large-scale cohort studies. Research findings were published in Metabolites journal (Metabolomics Society).

humanmetabolome.com
5Keio University Institute for Advanced Biosciences (IAB)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

HMT maintains an ongoing technical collaboration with Keio University's IAB. The CE-MS technology was originally developed in 2002 by Professor Tomoyoshi Soga of IAB (HMT co-founder). Professor Masaru Tomita, Director of IAB (HMT co-founder), is a recognized leader in computational biology and metabolomics. HMT develops its CE-MS method under joint research agreements, contributing to the advancement and popularization of metabolomics.

humanmetabolome.com
Strategic tierSupportingTypeTechnology or Integration
Description

HMT develops its CE-MS method under a joint research agreement with Agilent Technologies, Inc. Agilent provides the CE instrumentation component of HMT's CE-MS platform. This is a technology partnership supporting HMT's core analytical infrastructure.

Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

LKLS Co., Ltd. is an authorized distributor of HMT services in Korea. Located at #241, 100 Sinusil-ro, Hanam-si, Gyeonggi-do 12995, Korea. LKLS handles local sales, customer support, and sample logistics for Korean customers.

8GenDiscovery Biotechnology, Inc. (Taiwan)
Strategic tierSupportingTypeChannel Partner/ Reseller/ Distributor
Description

GenDiscovery Biotechnology, Inc. is an authorized distributor of HMT services in Taiwan. Located at 25F-3, No.97, Sec. 1, Xintai 5th Rd., Xizhi Dist., New Taipei City 221, Taiwan. GenDiscovery handles local sales, customer support, and sample logistics for Taiwanese customers.

humanmetabolome.com
Recent move13 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-based leader in commissioned metabolomics and lipidomics analysis services for pharma and academia; directly overlaps with HMT's core untargeted/targeted metabolomics service model.

TypeOthers
Description

Supplier of the CE and MS instrumentation underpinning HMT's platform and a technology partner; an enabling ecosystem participant rather than a direct competitor.

TypeDirect peer
Description

China-based metabolomics and multi-omics contract analysis provider serving academic and industry researchers, comparable in service model and Asia-Pacific footprint.

TypeDirect peer
Description

US metabolomics-driven discovery services company providing large-scale MS-based metabolite profiling for biomarker and drug development, closely aligned with HMT's platform.

TypeDirect peer
Description

Finnish company offering NMR-based blood metabolomics for large cohorts and biomarker discovery, overlapping HMT's large-scale cohort metabolomics offering.

TypeDirect peer
Description

Contract lab offering metabolomics, proteomics and lipidomics analysis services, mirroring HMT's expanding multi-omics service portfolio.

TypeBroad incumbent
Description

Global bioanalytical testing and CRO network offering metabolomics and specialized lab services as part of a much broader portfolio overlapping HMT's contract analysis business.

8Chenomx
TypeEmerging player
Description

Provider of NMR metabolomics software and analysis services, comparable to HMT's combined measurement-plus-analytics-software approach.

TypeEmerging player
Description

UK company focused on breath-based metabolomics/VOC analysis and biomarker discovery, overlapping HMT's non-invasive metabolite measurement (skin gas) and biomarker services.

TypeDirect peer
Description

Austrian provider of targeted metabolomics and lipidomics kits and services using MS; competes directly in targeted metabolite quantification for biomarker research.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Human Metabolome Technologies

Metabolomics Serviceshumanmetabolome.com

Human Metabolome Technologies is a Japan-based contract research organization that provides CE-MS and LC-MS-based metabolomics profiling and biomarker discovery services to pharmaceutical, academic, food/functional-ingredient, and government research customers across Asia-Pacific, North America, and Europe.

What Human Metabolome Technologies does

Human Metabolome Technologies, Inc. (HMT) is a Japan-based biotechnology and metabolomics contract research company founded on July 1, 2003, by Professor Tomoyoshi Soga (developer of the CE-MS method at Keio University in 2002) and Professor Masaru Tomita, Director of Keio's Institute for Advanced Biosciences. The company is headquartered at 246-2 Mizukami Kakuganji, Tsuruoka, Yamagata, Japan, with sales operations in Tokyo (Chuo-ku) and a US subsidiary (Human Metabolome Technologies America, Inc.) in Boston, MA. HMT is listed on the Tokyo Stock Exchange (ticker: 6090) with 51–100 employees.

HMT's core technology platform is Capillary Electrophoresis Mass Spectrometry (CE-MS), developed jointly with Keio University and Agilent Technologies, with LC-MS and MS/MS platforms supplementing for lipophilic and broader-coverage metabolite analysis. The service catalog spans OMEGA Scan (untargeted polar metabolomics, 1.5–2x more metabolites vs. basic scan), LC-OMEGA Scan (untargeted lipidomics), Mediator Scan (400 lipid mediators), C-SCOPE (targeted quantitative glycolytic panel of 116 metabolites with three-point calibration), F-SCOPE (isotope flux analysis for C13/N15 tracing), D/L amino acid isomer analysis, and a patented peptidomics approach covering 1,000–10,000 mass range. The full platform measures more than 1,700 metabolites as of November 2025. Reports include PCA, HCA heat maps, pathway mapping, and expert biochemist interpretation, with standard turnaround of 4–8 weeks.

HMT operates a professional-services / CRO business model with quote-based, pay-as-you-go pricing that varies by analysis plan, sample count, and optional add-ons. The company serves pharmaceutical and biotechnology companies (drug discovery, biomarker, preclinical/clinical research), academic and medical research institutions (infectious disease, oncology, neuroscience, regenerative medicine), food and functional ingredient manufacturers (health-claim support, fermentation optimization), chemical/industrial biotech companies (metabolic flux analysis), and government/public-health research organizations. Distribution is hybrid: direct sales in Japan and North America, plus authorized distributors LKLS Co., Ltd. in Korea and GenDiscovery Biotechnology in Taiwan. Marketing is centered on recurring webinars, the Metabolite of the Week educational series, active participation in Japanese scientific conferences (BioJapan, Japanese Society for Bioscience/Biotechnology/Agricultural Chemistry, etc.), and direct inquiry handling through the website and account managers. Complementary revenue streams include biomarker discovery, healthcare solution packages (functional ingredient development, health claim prediction), analysis kits and consumables (centrifugal filters, miRNA panels), and strategic partnerships with MiRXES (miRNA), AutoPhagyGO (autophagy), and AIREX.

Human Metabolome Technologies firmographics

Firmographics
Name
Human Metabolome Technologies
Legal name
Human Metabolome Technologies, Inc.
Website
https://humanmetabolome.com
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
11–50 employees
Short description
Human Metabolome Technologies is a Japan-based contract research organization that provides CE-MS and LC-MS-based metabolomics profiling and biomarker discovery services to pharmaceutical, academic, food/functional-ingredient, and government research customers across Asia-Pacific, North America, and Europe.
Ownership category
akta.pro rank

Human Metabolome Technologies industry classification

Industry
Product category
Metabolomics Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYHLAGANAG
Metabolomics & Lipidomics Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Metabolomics services
  • Mass spectrometry analysis
  • Biomarker discovery
  • CE-MS platforms
  • Metabolome profiling

Where Human Metabolome Technologies is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Human Metabolome Technologies business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Metabolome Analysis Services: HMT's primary revenue stream, offering commissioned metabolomics analysis services across multiple platforms (CE-MS, LC-MS, MS/MS). Services include various analysis plans such as Basic Scan, Advanced Scan, ω Scan, C-SCOPE, F-SCOPE, Dual Scan, Mediator Scan, and optional add-ons. Pricing is quote-based and varies by plan, sample count, and optional analyses. Reports are delivered in PDF with Excel numerical data within 4–8 weeks typically.
  2. Biomarker Discovery: HMT conducts research and development of biomarkers related to mental illness and lifestyle diseases, contributing to preventive and personalized medicine. This includes support for cohort study-based biomarker searches, collaborating with academic and clinical partners.
  3. Healthcare Solution Services: HMT provides comprehensive support services for functional ingredient development, including biomarker exploration packages, promotion data packages, health claim prediction packages, and fermentation upcycling material development support. Also includes proteome analysis, human skin gas measurement, autophagy activity evaluation, miRNA analysis, and exosome-related analysis services.
  4. Analysis Kit and Consumables Sales: HMT sells centrifugal filtration filters and miRNA analysis panels/primers as consumable products alongside its service offerings.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goC-SCOPE and quantitative panels — absolute concentration reporting
Unit PricingPay-as-you-goNon-quantitative panels (Basic Scan, Advanced Scan, ω Scan, Dual Scan, Mediator Scan, F-SCOPE) — relative area value reporting

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Human Metabolome Technologies product offering

Product offering

Core offering

Human Metabolome Technologies (HMT) provides commissioned metabolome analysis services using proprietary Capillary Electrophoresis Mass Spectrometry (CE-MS) and Liquid Chromatography Mass Spectrometry (LC-MS) platforms. The company offers targeted and untargeted metabolomics profiling across more than 1,700 metabolites from biological samples including biofluids, tissues, cells, food, and microbial samples, serving pharmaceutical, academic, food science, and clinical research customers.

Product overview

Human Metabolome Technologies (HMT) offers a comprehensive metabolomics service platform based on capillary electrophoresis mass spectrometry (CE-MS) and liquid chromatography mass spectrometry (LC-MS) technologies. The core offerings include OMEGA Scan for untargeted polar metabolite analysis, Basic/Advanced Scan for hydrophilic profiling, C-SCOPE for quantitative glycolytic panel analysis, Mediator Scan for 400 lipid mediator targets, Dual Scan for combined polar/lipophilic analysis, F-SCOPE for isotope flux analysis, and LC-OMEGA for lipid analysis. Supporting services include biomarker discovery, peptidomics, amino acid analysis, D/L amino acid isomers, tryptophan metabolism panels, sample quality analysis, and flux analysis. HMT also provides specialized services including cohort study packs, proteome analysis, skin gas measurement, autophagy assessment, miRNA analysis (via MiRXES partnership), exosome analysis, and functional ingredient development support with health claim prediction. The platform covers applications in infectious disease, cancer metabolism, microbiome, metabolic diseases, neuroscience, regenerative medicine, and food metabolomics.

Differentiator

Problem solved

Functional benefit

Products and services

  • OMEGA Scan HMT's signature untargeted metabolomics platform based on CE-MS, optimized for high-sensitivity analysis of polar, semi-volatile, hydrophilic, and charged metabolites from any biological source. Detects 1.5 to 2 times more metabolites than standard Basic Scan.
  • Basic Scan Multi-purpose CE-MS profiling service for a wide range of hydrophilic metabolites, including energy metabolism intermediates, for general screening applications.
  • Advanced Scan Comprehensive CE-MS analysis including unknown metabolites for extended-range hydrophilic metabolite profiling with identification capabilities.
  • C-SCOPE Targeted Glycolytic Panel Targeted quantitative panel of 116 metabolites in the glycolytic pathway, pentose phosphate pathway, TCA cycle, amino acids, and urea cycle using three-point calibration for absolute quantification. Used for cancer, Warburg effect, and mitochondrial metabolism research.
  • Q110 and Q353 Quantitative Polar Panels Targeted panels of 110 or 353 polar metabolites respectively, representing a wide range of metabolite classes. Used with untargeted metabolomics such as OMEGA Scan for comprehensive profiling.
  • Mediator Scan (MSCAN) Targeted panel covering 400 bioactive lipids including oxylipins, omega fatty acids, inflammatory lipids (HETEs), EPA, DHA, corticosteroids, lysophospholipids, and middle to very long chain acyl carnitines. Used for inflammation and immune response studies.
  • Dual Scan Low-cost option profiling both polar and lipophilic metabolites using Agilent CE-TOFMS system. Identifies more than 1,300 metabolites covering over 1,000 hydrophilic/ionic and 300 lipophilic metabolites. Ideal for plant extracts, agricultural products, and fermentation broths.
  • LC-OMEGA Scan Untargeted lipid metabolite analysis using HPLC-MS methods focusing on lipophilic metabolites with high-resolution chromatography and high-resolution high-sensitivity FTMS.
  • F-SCOPE Targeted Flux Panel Targets 54 polar metabolites in the glycolytic pathway, TCA cycle, purines and pyrimidines, urea cycle and amino acids to measure C13 and N15 heavy atom labeled metabolite transformations for metabolic flux analysis. Used for in-vivo measurements of glucose oxidation and glutamine metabolism.
  • Peptidomics Patented peptidomics approach offering a small peptide library (100 to 1,000 mass) with OMEGA Scan advanced option for bioactive 2-mers to 5-mers, and a patented approach covering 1,000 to 10,000 mass mid-molecular weight range not accessible by standard metabolomics.
  • D/L Amino Acids Panel Unique targeted panel of 25 D and L amino acids using derivatization with an optical-center ligand that separates and identifies D and L isomers not resolvable in typical metabolomic chromatography.
  • Tryptophan Metabolism Pathway Panel Targeted platform of the tryptophan pathway for inflammation, immune system and neurological condition research.
  • Amino Acid Analysis Measures all 20 common amino acids including citrulline and ornithine for biological function analysis including antioxidant activity and ATP synthesis.
  • Sample Quality Analysis Data assessment evaluating sample stability using known markers for thermal degradation, hemolysis, platelet contamination and long-term storage to survey biofluids and tissues prior to statistical analysis.
  • Fit-4 Purpose Assays Full-service quantitative assays using various forms of capillary electrophoresis and liquid chromatography mass spectrometry, with options validated for research or clinical use.
  • Flux Analysis Metabolic flux determination using isotopically labeled substrates to trace metabolites and elucidate active metabolic pathways.
  • Biomarker Discovery Metabolomic profiling service supporting biomarker discovery for disease detection, diagnostic markers, and predictive markers in clinical studies.
  • Cohort Study Pack Comprehensive support service for cohort studies including metabolomics analysis and biomarker discovery for population health research, incorporating large-scale data correction methodology.
  • Metabololo-Index (メタボロインデックス) Biomarker index service using metabolomic data and machine learning algorithms for health assessment and disease prediction.
  • Proteome Analysis Proteomics analysis service complementing metabolome analysis for comprehensive molecular profiling.
  • Human Skin Gas Measurement Specialized analysis service for measuring volatile metabolites from human skin for non-invasive metabolic profiling.
  • Autophagy Activity Assessment Service for evaluating autophagy activity through metabolomic analysis, supporting research in cellular degradation and renewal processes.
  • miRNA Analysis (MiRXES ID3EAL) miRNA analysis service using ID3EAL technology through partnership with MiRXES for gene expression analysis.
  • Exosome-Related Analysis Analysis service for exosome samples supporting extracellular vesicle research and biomarker discovery.
  • Functional Ingredient Development Support Service Comprehensive support package including functional ingredient exploration, promotion data, and health claim prediction packages for functional food development.
  • Health Claim Prediction Package Predictive service using proprietary algorithms to predict health claims for functional foods based on metabolomic analysis.
  • Bio-manufacturing Production Enhancement Support Service Support service for bio-manufacturing productivity enhancement using metabolomics for process optimization, including fermentation upcycling material development support.
  • Analysis Kits and Consumables Sale of centrifugal filter units and miRNA analysis panels and primers for customer self-directed analysis, sold alongside service offerings.
  • Food Metabolomics Application Application offering covering analysis of food components, metabolic changes during manufacturing, preparation and storage, functional component exploration, and dietary effect assessment for food science researchers and manufacturers.
  • Regenerative Medicine Application Application offering supporting stem cell research, cell differentiation studies, and regenerative medicine applications for researchers in regenerative medicine and cell biology.

Quantifiable outcome

  • Over 1,700 metabolites measurable in metabolome analysis service as of November 2025
  • +3 more outcomes

Companies that use Human Metabolome Technologies

Customer profile

Named customers8 records

Segments5 records

Ideal customer profiles4 records

Human Metabolome Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature9 records

Human Metabolome Technologies partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and supporting.

  • AutoPhagyGO Inc.coreStrategic or Co-development Partner · 1 August 2023AutoPhagyGO Inc. and HMT entered a business partnership to advance autophagy research and social implementation. The partnership involves joint webinars and collaboration on autophagy activity evaluation services. In 2025, the collaboration achieved the world's first 'autophagy certification' for NMN using metabolomics evidence, demonstrating the application of HMT's metabolomics in substantiating health claims.
  • AIREX Co., Ltd.coreStrategic or Co-development Partner · 1 May 2022AIREX and HMT entered a business partnership. Details of the collaboration are not fully specified in available sources but the partnership is listed as a formal business alliance alongside other strategic partnerships.
  • MiRXES Pte Ltd.coreStrategic or Co-development Partner · 1 September 2021MiRXES and HMT entered a business partnership for miRNA analysis services. HMT provides commissioned miRNA analysis services using MiRXES's ID3EAL technology, and offers MiRXES miRNA analysis panels and primers for sale. The partnership expands HMT's service offerings beyond metabolomics into RNA analysis.
  • Hirosaki University COIcoreStrategic or Co-development Partner · 1 May 2019HMT established a joint course 'Department of Metabolomics Innovation' at Hirosaki University Graduate School of Medicine in May 2019. The collaboration involves metabolome analysis of plasma and urine samples from participants in the Iwaki Health Promotion Project (cohort of over 2,000 participants with 10+ years of health data). Joint research has produced published methods for large-scale metabolome data correction, enabling reliable biomarker discovery in large-scale cohort studies. Research findings were published in Metabolites journal (Metabolomics Society).
  • Keio University Institute for Advanced Biosciences (IAB)coreStrategic or Co-development PartnerHMT maintains an ongoing technical collaboration with Keio University's IAB. The CE-MS technology was originally developed in 2002 by Professor Tomoyoshi Soga of IAB (HMT co-founder). Professor Masaru Tomita, Director of IAB (HMT co-founder), is a recognized leader in computational biology and metabolomics. HMT develops its CE-MS method under joint research agreements, contributing to the advancement and popularization of metabolomics.
  • Agilent Technologies, Inc.supportingTechnology or IntegrationHMT develops its CE-MS method under a joint research agreement with Agilent Technologies, Inc. Agilent provides the CE instrumentation component of HMT's CE-MS platform. This is a technology partnership supporting HMT's core analytical infrastructure.
  • LKLS Co., Ltd. (Korea)supportingChannel Partner/ Reseller/ DistributorLKLS Co., Ltd. is an authorized distributor of HMT services in Korea. Located at #241, 100 Sinusil-ro, Hanam-si, Gyeonggi-do 12995, Korea. LKLS handles local sales, customer support, and sample logistics for Korean customers.
  • GenDiscovery Biotechnology, Inc. (Taiwan)supportingChannel Partner/ Reseller/ DistributorGenDiscovery Biotechnology, Inc. is an authorized distributor of HMT services in Taiwan. Located at 25F-3, No.97, Sec. 1, Xintai 5th Rd., Xizhi Dist., New Taipei City 221, Taiwan. GenDiscovery handles local sales, customer support, and sample logistics for Taiwanese customers.

Scale indicators7 records

Recent moves13 records

Expansion highlights6 records

Human Metabolome Technologies competitors and assessment

Company assessment

Direct peers

  • Metabolon: US-based leader in commissioned metabolomics and lipidomics analysis services for pharma and academia; directly overlaps with HMT's core untargeted/targeted metabolomics service model.
  • Metware Biotechnology: China-based metabolomics and multi-omics contract analysis provider serving academic and industry researchers, comparable in service model and Asia-Pacific footprint.
  • Sapient Bioanalytics: US metabolomics-driven discovery services company providing large-scale MS-based metabolite profiling for biomarker and drug development, closely aligned with HMT's platform.
  • Nightingale Health: Finnish company offering NMR-based blood metabolomics for large cohorts and biomarker discovery, overlapping HMT's large-scale cohort metabolomics offering.
  • Creative Proteomics: Contract lab offering metabolomics, proteomics and lipidomics analysis services, mirroring HMT's expanding multi-omics service portfolio.
  • Biocrates Life Sciences: Austrian provider of targeted metabolomics and lipidomics kits and services using MS; competes directly in targeted metabolite quantification for biomarker research.

Others

  • Agilent Technologies: Supplier of the CE and MS instrumentation underpinning HMT's platform and a technology partner; an enabling ecosystem participant rather than a direct competitor.

Broad incumbents

  • Eurofins Scientific: Global bioanalytical testing and CRO network offering metabolomics and specialized lab services as part of a much broader portfolio overlapping HMT's contract analysis business.

Emerging players

  • Chenomx: Provider of NMR metabolomics software and analysis services, comparable to HMT's combined measurement-plus-analytics-software approach.
  • Owlstone Medical: UK company focused on breath-based metabolomics/VOC analysis and biomarker discovery, overlapping HMT's non-invasive metabolite measurement (skin gas) and biomarker services.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Human Metabolome Technologies social profiles

Digital presence

Human Metabolome Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Human Metabolome Technologies leadership team

Management profile

Number of profiles

Profiles5 records

Human Metabolome Technologies subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Human Metabolome Technologies funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Human Metabolome Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Human Metabolome Technologies

What does Human Metabolome Technologies do?

Human Metabolome Technologies (HMT) provides commissioned metabolome analysis services using proprietary Capillary Electrophoresis Mass Spectrometry (CE-MS) and Liquid Chromatography Mass Spectrometry (LC-MS) platforms. The company offers targeted and untargeted metabolomics profiling across more than 1,700 metabolites from biological samples including biofluids, tissues, cells, food, and microbial samples, serving pharmaceutical, academic, food science, and clinical research customers.

Is Human Metabolome Technologies a public or private company?

Human Metabolome Technologies is a private company. It is classified as public and is currently operating.

When was Human Metabolome Technologies founded?

Human Metabolome Technologies was founded in 2003. It employs 11 to 50 people.

Where is Human Metabolome Technologies based?

Human Metabolome Technologies is headquartered in Boston, United States, in the North America region.

How does Human Metabolome Technologies make money?

Four revenue lines are on record. Metabolome Analysis Services are the primary driver. The others are biomarker Discovery, healthcare Solution Services and analysis Kit and Consumables Sales.

Who are Human Metabolome Technologies's main competitors?

Direct peers on record are Metabolon, Metware Biotechnology, Sapient Bioanalytics, Nightingale Health, Creative Proteomics and Biocrates Life Sciences. Agilent Technologies is listed as an others. Eurofins Scientific is listed as a broad incumbent. Emerging players are Chenomx and Owlstone Medical.

Does Human Metabolome Technologies have an API?

No public API is recorded for Human Metabolome Technologies.

What industry is Human Metabolome Technologies in?

Human Metabolome Technologies's product category is Metabolomics Services. Its primary akta.pro industry code is HLAGANAG, Metabolomics & Lipidomics Services, with a secondary code of HLAGANAB, Proteomics & Mass Spectrometry Services. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketWatchHuman Metabolome Tech 1Q Loss Y3.00M Vs Loss Y97.00MHuman Metabolome Technologies reported Q1 2026 revenue of Y253 million, up from Y192 million in 2025, with a net loss of Y3 million versus a Y97 million loss in the same period. Operating profit was Y4 million, and pretax profit was Y0 million.Third NewsDIRECTOR6 Implementation Case Study at Human Metabolome TechnologiesHuman Metabolome Technologies, a Tokyo-based contract analysis firm, implemented Simtops Inc.'s DIRECTOR6 scheduling system after finding off-the-shelf products inadequate and custom development too costly. Simtops engineers provided eight months of training and configuration support. HMT now monitors productivity across three divisions and plans to expand automated scheduling and adopt i-Reporter electronic documentation.PrtimesRhelixa Inc. has partnered with Human Metabolome Technologies Inc. for NAD+ testing services for clinics.Rhelixa and Human Metabolome Technologies signed a contract to jointly develop an NAD+ test for clinics, using HMT's high-sensitivity blood NAD+ analysis. The test will complement Rhelixa's Epigenetic Clock test to track changes from aging care and supplements. Both companies plan to develop further initiatives integrating their metabolome and epigenome technologies.PR NewswireMetabolomics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2014 - 2024This article presents a global market analysis and forecast for the metabolomics industry from 2014 to 2024, covering market segmentation by technique (separation and detection methods), application (drug assessment, biomarker discovery, nutrigenomics, clinical toxicology), and geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The report identifies key market drivers including technological advances in molecular biology and increasing research funding, while noting restraints such as shortage of skilled professionals and low adoption rates of advanced products. Major companies profiled as market participants include Thermo Fisher Scientific, Agilent Technologies, Biocrates Life Sciences AG, Shimadzu Corporation, Waters Corporation, Human Metabolome Technologies, Inc., LECO Corporation, Metabolon, Inc., Bio-Rad Laboratories, Inc., and Bruker Corporation.GlobeNewswireMYOS Corporation Announces Research Agreement With Human Metabolome Technologies America to Conduct Clinical Metabolomic Studies in Subjects Using Fortetropin(TM)MYOS Corporation announced a research agreement with Human Metabolome Technologies to conduct clinical metabolomic studies on Fortetropin in healthy male subjects. The study aims to identify metabolites with pro-myogenic activity and examine effects on glucose and fat metabolism, with results expected in Q4 2014.